An integrated approach to defining genetic and environmental determinants for major clinical outcomes involving vitamin D

Molecular Diagnosis and Therapy

Volumn 18, Issue 3, 2014, Pages 261-272

  Berlanga Taylor, Antonio J ^a   Knight, Julian C ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; VDR PROTEIN, HUMAN; VITAMIN D BINDING PROTEIN;

AUTOIMMUNE DISEASE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENVIRONMENTAL EXPOSURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEART INFARCTION; HIP FRACTURE; HUMAN; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TRANSLATIONAL RESEARCH; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; BLOOD; COMPLICATION; DIET SUPPLEMENTATION; DISEASE; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS (TOPIC); METABOLISM; PATHOLOGY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARDS;

DIETARY SUPPLEMENTS; DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMIN D-BINDING PROTEIN;

EID: 84902371282     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-014-0087-2     Document Type: Review

References (97)

1. Bouillon R, Bischoff-Ferrari H, Willett W. Vitamin D and health: perspectives from mice and man. J Bone Miner Res. 2008;23(7):974-9. doi:10.1359/jbmr.080420. (Pubitemid 351915717)
2. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol. 2008;4(8):404-12. doi:10.1038/ncprheum0855.
3. Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol. 2011;7(6):337-45. doi:10.1038/nrendo.2010.226.
4. Badenhoop K, Kahles H, Penna-Martinez M. Vitamin D, immune tolerance, and prevention of type 1 diabetes. Curr Diabetes Rep. 2012;12(6):635-42.
5. Giovannoni G, Ebers G. Multiple sclerosis: the environment and causation. Curr Opin Neurol. 2007;20(3):261-8. doi:10.1097/WCO.0b013e32815610c2. (Pubitemid 46743106)
6. Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA. 2012;308(18):1898-905. doi:10.1001/jama.2012. 17304.
7. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90(15613415):1888-96. (Pubitemid 40464064)
8. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81. doi:10.1056/NEJMra070553.
9. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80(6 Suppl):1689S-96S 80/6/1689S.
10. Horst RL, Reinhardt TA, Reddy GS. Vitamin D metabolism. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D, vol I, 2nd ed. London, UK: Elsevier Academic Press; 2005. p. 15-36.
11. Hsu F, Kent WJ, Clawson H, Kuhn RM, Diekhans M, Haussler D. The UCSC known genes. Bioinformatics. 2006;22(16500937):1036-46.
12. Pike JW, Meyer MB. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin N Am. 2010;39(20511050):255-69.
13. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-8. doi:10.1210/jc.2010-2704.
14. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376(9736):180-8. doi:10.1016/S0140-6736(10) 60588-0.
15. Karohl C, Su S, Kumari M, Tangpricha V, Veledar E, Vaccarino V, et al. Heritability and seasonal variability of vitamin D concentrations in male twins. Am J Clin Nutr. 2010. doi:10.3945/ajcn.2010.30176.
16. Orton SM, Ebers GC. Heritability of serum vitamin D concentrations: twin studies. Am J Clin Nutr. 2011. doi:10.3945/ajcn.110.009423.
17. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet. 2010;19(13):2739-45. doi:10.1093/hmg/ddq155.
18. Whitfield GK, Dang HTL, Schluter SF, Bernstein RM, Bunag T, Manzon LA, et al. Cloning of a functional vitamin D receptor from the lamprey (Petromyzon marinus), an ancient vertebrate lacking a calcified skeleton and teeth. Endocrinology. 2003;144(12746335):2704-16. (Pubitemid 36629924)
19. Holick MF. Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets. 2011;12(1):4-18.
20. Grossman SR, Shlyakhter I, Karlsson EK, Byrne EH, Morales S, Frieden G, et al. A composite of multiple signals distinguishes causal variants in regions of positive selection. Science. 2010;327(5967):883-6. doi:10.1126/science. 1183863.
21. Jablonski NG, Chaplin G. The evolution of human skin coloration. J Hum Evol. 2000;39(1):57-106. doi:10.1006/jhev.2000.0403. (Pubitemid 30480792)
22. Neer RM. The evolutionary significance of vitamin D, skin pigment, and ultraviolet light. Am J Phys Anthropol. 1975;43(3):409-16. doi:10.1002/ajpa. 1330430322.
23. Kitanaka S. Genetic basis for skeletal disease: hereditary rickets. Clin Calcium. 2010;20(8):1238-44. doi:CliCa100812381244.
24. Tiosano D, Wildbaum G, Gepstein V, Verbitsky O, Weisman Y, Karin N, et al. The role of vitamin D receptor in innate and adaptive immunity: a study in hereditary vitamin D-resistant rickets patients. J Clin Endocrinol Metab. 2013;98(4):1685-93. doi:10.1210/jc.2012-3858.
25. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260-8. doi:10.1016/s1473-3099(13)70001-x.
26. Andraos C, Koorsen G, Knight JC, Bornman L. Vitamin D receptor gene methylation is associatedwith ethnicity, tuberculosis, and TaqI polymorphism. Hum Immunol. 2011;72(21168462):262-8.
27. Smolders J, Peelen E, Thewissen M, Menheere P, Tervaert JW, Hupperts R, et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev. 2009;8(7):621-6. doi:10.1016/j.autrev.2009.02.009.
28. Ji GR, Yao M, Sun CY, Li ZH, Han Z. BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and risk of fracture in Caucasians: a meta-analysis. Bone. 2010;47(3):681-6. doi:10.1016/j.bone.2010.06. 024.
29. Li L, Wu B, Liu JY, Yang LB. Vitamin D receptor gene polymorphisms and type 2 diabetes: a meta-analysis. Arch Med Res. 2013;44(3):235-41. doi:10.1016/j.arcmed.2013.02.002.
30. Neyestani TR, Djazayery A, Shab-Bidar S, Eshraghian MR, Kalayi A, Shariatzadeh N, et al. Vitamin D receptor Fok-I polymorphism modulates diabetic host response to vitamin D intake: need for a nutrigenetic approach. Diabetes Care. 2013;36(3):550-6. doi:10.2337/dc12-0919.
31. Yokoyama K, Nakashima A, Urashima M, Suga H, Mimura T, Kimura Y, et al. Interactions between serum vitamin D levels and vitamin D receptor gene FokI polymorphisms for renal function in patients with type 2 diabetes. PLoS One. 2012;7(12):e51171. doi:10.1371/journal.pone.0051171.
32. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep. 2011;38(6):3643-51. doi:10.1007/s11033-010-0477-4.
33. Ghelani AM, Samanta A, Jones AC, Mastana SS. Association analysis of TNFR2, VDR, A2M, GSTT1, GSTM1, and ACE genes with rheumatoid arthritis in South Asians and Caucasians of East Midlands in the United Kingdom. Rheumatol Int. 2011;31(10):1355-61. doi:10.1007/s00296-010-1478-2.
34. Karray EF, Ben Dhifallah I, Ben Abdelghani K, Ben Ghorbel I, Khanfir M, Houman H, et al. Associations of vitamin D receptor gene polymorphisms FokI and BsmI with susceptibility to rheumatoid arthritis and Behcet's disease in Tunisians. Joint Bone Spine. 2012;79(2):144-8. doi:10.1016/j.jbspin.2011.06.003.
35. Hussien YM, Shehata A, Karam RA, Alzahrani SS, Magdy H, El-Shafey AM. Polymorphism in vitamin D receptor and osteoprotegerin genes in Egyptian rheumatoid arthritis patients with and without osteoporosis. Mol Biol Rep. 2013;40(5):3675-80. doi:10.1007/s11033-012-2443-9.
36. Ortlepp JR, Krantz C, Kimmel M, von Korff A, Vesper K, Schmitz F, et al. Additive effects of the chemokine receptor 2, vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years. Int J Cardiol. 2005;105(1):90-5. doi:10.1016/j.ijcard.2005.03.004. (Pubitemid 41406366)
37. Montenegro MF. Tru9 I restriction polymorphism in vitamin D receptor may cause failure of PCR amplification in Bsm I polymorphism. Int J Cardiol. 2007;114(3):414. doi:10.1016/j.ijcard.2005.12.003 author reply 5.
38. Fu Y, Li J, Zhang Y. Polymorphisms in the vitamin D receptor gene and the lung cancer risk. Tumour Biol. 2013. doi:10.1007/s13277-013-1176-2.
39. Song GG, Lee YH. Vitamin D receptor FokI, BsmI, ApaI, and TaqI polymorphisms and susceptibility to ovarian cancer: a meta-analysis. Immunol Investig. 2013;42(7):661-72. doi:10.3109/08820139.2013.822881.
40. Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29(9):3511-36.
41. Guo YJ, Shi ZM, Liu JD, Lei N, Chen QH, Tang Y. Meta-analysis of the relation between the VDR gene TaqI polymorphism and genetic susceptibility to prostate cancer in Asian populations. Asian Pac J Cancer Prev. 2012;13(9):4441-4.
42. Guo Z, Wen J, Kan Q, Huang S, Liu X, Sun N, et al. Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-analysis involving 21,756 subjects. Tumour Biol. 2013;34(5):3189-200. doi:10.1007/s13277-013-0889-6.
43. Perna L, Hoffmeister M, Schottker B, Arndt V, Haug U, Holleczek B, et al. Vitamin D receptor polymorphism and colorectal cancer-specific and all-cause mortality. Cancer Epidemiol. 2013. doi:10.1016/j.canep.2013.09.007.
44. Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen BC. Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol. 2012;18(14):1672-9. doi:10.3748/wjg.v18.i14.1672.
45. Wang J, He Q, Shao YG, Ji M, Bao W. Associations between vitamin D receptor polymorphisms and breast cancer risk. Tumour Biol. 2013. doi:10.1007/s13277-013-0967-9.
46. Xu J, Li H, Gu L, Zhou X. Association between vitamin D receptor poly(A) polymorphism and breast cancer risk: a meta-analysis. Tumour Biol. 2013. doi:10.1007/s13277-013-1082-7.
47. Zhou ZC, Wang J, Cai ZH, Zhang QH, Cai ZX, Wu JH. Association between vitamin D receptor gene Cdx2 polymorphism and breast cancer susceptibility. Tumour Biol. 2013. doi:10.1007/s13277-013-0919-4.
48. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119-24. doi:10.1038/nature11582.
49. ANZgene. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41(7):824-8. doi:10.1038/ng.396.
50. Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Sakashita M, et al. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet. 2012;44(11):1222-6. doi:10.1038/ng.2438.
51. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214-9. doi:10.1038/nature10251.
52. Dong J, Hu Z, Wu C, Guo H, Zhou B, Lv J, et al. Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet. 2012;44(8):895-9. doi:10.1038/ng.2351.
53. Adams LA, White SW, Marsh JA, Lye SJ, Connor KL, Maganga R, et al. Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease. Hepatology. 2013;57(2):590-600. doi:10.1002/hep.26184.
54. Inouye M, Ripatti S, Kettunen J, Lyytikainen LP, Oksala N, Laurila PP, et al. Novel loci for metabolic networks and multitissue expression studies reveal genes for atherosclerosis. PLoS Genet. 2012;8(8):e1002907. doi:10.1371/journal. pgen.1002907.
55. Boger CA, Chen MH, Tin A, Olden M, Kottgen A, de Boer IH, et al. CUBN is a gene locus for albuminuria. J Am Soc Nephrol. 2011;22(3):555-70. doi:10.1681/asn.2010060598.
56. Furney SJ, Simmons A, Breen G, Pedroso I, Lunnon K, Proitsi P, et al. Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol Psychiatry. 2011;16(11):1130-8. doi:10.1038/mp.2010.123.
57. Hazra A, Kraft P, Lazarus R, Chen C, Chanock SJ, Jacques P, et al. Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hum Mol Genet. 2009;18(23):4677-87. doi:10.1093/hmg/ddp428.
58. Tanaka T, Scheet P, Giusti B, Bandinelli S, Piras MG, Usala G, et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet. 2009;84(4):477-82. doi:10.1016/j.ajhg.2009.02.011.
59. Lowe JK, Maller JB, Pe'er I, Neale BM, Salit J, Kenny EE, et al. Genome-wide association studies in an isolated founder population from the Pacific Island of Kosrae. PLoS Genet. 2009;5(2):e1000365. doi:10.1371/journal. pgen.1000365.
60. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet. 2010;42(3):210-5. doi:10.1038/ng.531.
61. Sempos CT, Durazo-Arvizu RA, Dawson-Hughes B, Yetley EA, Looker AC, Schleicher RL, et al. Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. J Clin Endocrinol Metab. 2013;98(7):3001-9. doi:10.1210/jc.2013-1333.
62. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2011(7):CD007470. doi:10.1002/14651858.CD007470.pub2.
63. Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev. 2012;12(2):127-36. doi:10.1016/j.autrev.2012.07.007.
64. Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012;367(1):40-9. doi:10.1056/NEJMoa1109617.
65. Khan H, Kunutsor S, Franco OH, Chowdhury R. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc Nutr Soc. 2013;72(1):89-97.
66. George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med. 2012;29(8):e142-50. doi:10.1111/j.1464-5491.2012.03672.x.
67. Song GG, Bae SC, Lee YH. Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis. Clin Rheumatol. 2012;31(12):1733-9. doi:10.1007/s10067-012-2080-7.
68. Varenna M, Manara M, Cantatore FP, Del Puente A, Di Munno O, Malavolta N, et al. Determinants and effects of vitamin D supplementation on serum 25-hydroxy-vitamin D levels in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(5):714-9.
69. Racovan M, Walitt B, Collins CE, Pettinger M, Parks CG, Shikany JM, et al. Calcium and vitamin D supplementation and incident rheumatoid arthritis: the Women's Health Initiative Calcium plus Vitamin D trial. Rheumatol Int. 2012;32(12):3823-30. doi:10.1007/s00296-011-2268-1.
70. Gotsman I, Shauer A, Zwas DR, Hellman Y, Keren A, Lotan C, et al. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail. 2012;14(4):357-66. doi:10.1093/eurjhf/hfr175.
71. Tomson J, Emberson J, Hill M, Gordon A, Armitage J, Shipley M, et al. Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths. Eur Heart J. 2013;34(18):1365-74. doi:10.1093/eurheartj/ehs426.
72. Gunta SS, Thadhani RI, Mak RH. The effect of vitamin D status on risk factors for cardiovascular disease. Nat Rev Nephrol. 2013. doi:10.1038/nrneph. 2013.208.
73. Robinson-Cohen C, Hoofnagle AN, Ix JH, Sachs MC, Tracy RP, Siscovick DS, et al. Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA. 2013;310(2):179-88. doi:10.1001/jama.2013.7228.
74. Correia LC, Sodre F, Garcia G, Sabino M, Brito M, Kalil F, et al. Relation of severe deficiency of vitamin D to cardiovascular mortality during acute coronary syndromes. Am J Cardiol. 2013;111(3):324-7. doi:10.1016/j. amjcard.2012.10.006.
75. Liu L, Chen M, Hankins SR, Nunez AE, Watson RA, Weinstock PJ, et al. Serum 25-hydroxyvitamin D concentration and mortality from heart failure and cardiovascular disease, and premature mortality from all-cause in United States adults. Am J Cardiol. 2012;110(6):834-9. doi:10.1016/j.amjcard.2012.05.013.
76. Masson S, Solomon S, Angelici L, Latini R, Anand IS, Prescott M, et al. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail. 2010;16(12):964-70. doi:10.1016/j. cardfail.2010.06.417.
77. Schroten NF, Ruifrok WP, Kleijn L, Dokter MM, Sillje HH, Lambers Heerspink HJ, et al. Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). Am Heart J. 2013;166(2):357.e2-364.e2. doi:10.1016/j.ahj.2013.05.009.
78. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation. 2007;115(7):846-54. doi:10.1161/CIRCULATIONAHA.106.673491. (Pubitemid 46294725)
79. Picotto G, Liaudat AC, Bohl L, Tolosa de Talamoni N. Molecular aspects of vitamin D anticancer activity. Cancer Investig. 2012;30(8):604-14. doi:10.3109/07357907.2012.721039.
80. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011;128(6):1414-24. doi:10.1002/ijc.25439.
81. Yin L, Ordonez-Mena JM, Chen T, Schottker B, Arndt V, Brenner H. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis. Prev Med. 2013. doi:10.1016/j.ypmed.2013.08.026.
82. Helzlsouer KJ. Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):4-9. doi:10.1093/aje/ kwq119.
83. Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, et al. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1alpha-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013;73(9):970-8. doi:10.1002/pros.22644.
84. Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab. 2013;98(4):1498-507. doi:10.1210/jc.2012-4019.
85. Jorde R, Schirmer H, Wilsgaard T, Joakimsen RM, Mathiesen EB, Njolstad I, et al. Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality: the Tromso Study. PLoS One. 2012;7(5):e37295. doi:10.1371/journal.pone.0037295.
86. Dennis J, Hawken S, Krewski D, Birkett N, Gheorghe M, Frei J, et al. Bias in the case-only design applied to studies of gene-environment and gene-gene interaction: a systematic review and meta-analysis. Int J Epidemiol. 2011;40(5):1329-41. doi:10.1093/ije/dyr088.
87. Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet. 2005;6(4):287-98. doi:10.1038/nrg1578. (Pubitemid 40469048)
88. Khoury MJ, Wacholder S. Invited commentary: from genomewide association studies to gene-environment-wide interaction studies: challenges and opportunities. Am J Epidemiol. 2009;169(2):227-30. doi:10.1093/aje/kwn351 discussion 34-35.
89. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283-93. doi:10.1056/NEJMoa1310669.
90. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013;369(24):2304-12. doi:10.1056/NEJMoa1311388.
91. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294-303. doi:10.1056/NEJMoa1311386.
92. Chen L, Davey Smith G, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Med. 2008;5(3):e52. doi:10.1371/journal.pmed.0050052.
93. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-72. doi:10.1056/NEJMoa054013.
94. Mondul AM, Shui IM, Yu K, Travis RC, Stevens VL, Campa D, et al. Genetic variation in the vitamin D pathway in relation to risk of prostate cancer: results from the breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2013;22(4):688-96. doi:10.1158/1055-9965.epi-13-0007-t.
95. Tsilidis KK, Travis RC, Appleby PN, Allen NE, Lindstrom S, Schumacher FR, et al. Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Am J Epidemiol. 2012;175(9):926-35. doi:10.1093/aje/kwr423.
96. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011;377(9761):242-50. doi:10.1016/S0140-6736(10)61889-2.
97. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010;20(10):1352-60. doi:10.1101/gr.107920.110.